CAPR Capricor Therapeutics Inc.

5.68
-0.55  -9%
Previous Close 6.23
Open 6.06
Price To Book 5.26
Market Cap 19,687,555
Shares 3,467,523
Volume 1,220,243
Short Ratio
Av. Daily Volume 798,435

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 HOPE-2 interim data July 15, 2019 noted data on two secondary endpoints, p-values 0.0591 and 0.0389.
CAP-1002 HOPE-2
Duchenne Muscular Dystrophy (DMD)
Phase 2 data released May 12, 2017 - primary endpoint unlikely to be met.
CAP-1002 ALLSTAR
Myocardial infarction (heart attack)
Phase 2 completed. Waiting on data from additional study to determine future
Cenderitide
Ambulatory heart failure

Latest News

  1. Capricor Therapeutics News: Why CAPR Stock Is Skyrocketing Today
  2. Capicor Therapeutics' stock rockets on heavy volume after positive MD trial results
  3. Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy
  4. What Kind Of Shareholders Own Capricor Therapeutics, Inc. (NASDAQ:CAPR)?
  5. Capricor Therapeutics (CAPR) Reports Q1 Loss, Lags Revenue Estimates
  6. Capricor: 1Q Earnings Snapshot
  7. Capricor Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
  8. Capricor Therapeutics, Inc. to Host Earnings Call
  9. Capricor Therapeutics to Present First Quarter 2019 Financial Results and Recent Corporate Update on May 13
  10. Will Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Earnings Grow In The Years Ahead?
  11. Capricor Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
  12. Capricor Therapeutics to Present Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Update on March 28
  13. Capricor Therapeutics, Inc. (NASDAQ:CAPR): Commentary On Fundamentals
  14. Capricor Resumes Dosing of Enrolled Patients in HOPE-2 Clinical Trial for Duchenne Muscular Dystrophy
  15. 4 Healthcare Stocks Looking To Have A Strong Thursday (1/24/19)
  16. Neurology Publishes Study Reporting Significant Improvements in Duchenne Muscular Dystrophy Patients Treated with Capricor’s Novel Cell Therapy
  17. Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA
  18. Does Capricor Therapeutics, Inc.’s (NASDAQ:CAPR) CEO Pay Reflect Performance?
  19. Factors of Influence in 2019, Key Indicators and Opportunity within Halozyme Therapeutics, Capricor Therapeutics, Appian, Yext, Agile Therapeutics, and Corbus Pharmaceuticals — New Research Emphasizes Economic Growth